Patents by Inventor Charles Howard Mitch

Charles Howard Mitch has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists
    Patent number: 9056844
    Abstract: A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: June 16, 2015
    Assignee: Eli Lilly and Company
    Inventors: Bruce Anthony Dressman, Mark Donald Chappell, Adam Michael Fivush, Charles Howard Mitch, Paul Leslie Ornstein, Eric George Tromiczak, Tatiana Natali Vetman
  • 4-substituted-3-phenylsulfanylmethyl-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists
    Patent number: 8629169
    Abstract: A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Grant
    Filed: November 15, 2011
    Date of Patent: January 14, 2014
    Assignee: Eli Lilly and Company
    Inventors: Stephon Cornell Smith, Renhua Li, Charles Howard Mitch, Tatiana Natali Vetman
  • 4-SUBSTITUTED-3-BENZYLOXY-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS
    Publication number: 20130237573
    Abstract: A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: November 15, 2011
    Publication date: September 12, 2013
    Applicant: ELI LILLY AND COMPANY
    Inventors: Bruce Anthony Dressman, Mark Donald Chappell, Adam Michael Fivush, Charles Howard Mitch, Paul Leslie Ornstein, Eric George Tromiczak, Tatiana Natali Vetman
  • Opioid receptor antagonists
    Patent number: 8338611
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Grant
    Filed: January 6, 2011
    Date of Patent: December 25, 2012
    Assignee: Eli Lilly and Company
    Inventors: Charles Howard Mitch, Steven James Quimby
  • 4-SUBSTITUTED-3-PHENYLSULFANYLMETHYL-BICYCLO[3.1.0]HEXANE COMPOUNDS AS mGluR 2/3 ANTAGONISTS
    Publication number: 20120129902
    Abstract: A mGlu2/3 receptor antagonist of the formula: its uses, and methods for its preparation are described.
    Type: Application
    Filed: November 15, 2011
    Publication date: May 24, 2012
    Applicant: ELI LILLY AND COMPANY
    Inventors: Stephon Cornell SMITH, Renhua LI, Charles Howard MITCH, Tatiana Natali VETMAN
  • Kappa selective opioid receptor antagonist
    Patent number: 8173695
    Abstract: A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Grant
    Filed: April 9, 2010
    Date of Patent: May 8, 2012
    Assignee: Eli Lilly and Company
    Inventors: Nuria Diaz Buezo, David Lee McKinzie, Charles Howard Mitch, Concepcion Pedregal-Tercero
  • Opioid Receptor Antagonists
    Publication number: 20110105571
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: January 6, 2011
    Publication date: May 5, 2011
    Applicant: ELI LILLY AND COMPANY
    Inventors: Mark Donald Chappell, Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel
  • Opioid receptor antagonists
    Patent number: 7902372
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Grant
    Filed: April 2, 2008
    Date of Patent: March 8, 2011
    Assignee: Eli Lilly and Company
    Inventors: Mark Donald Chappell, Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel
  • KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST
    Publication number: 20100197669
    Abstract: A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Application
    Filed: April 9, 2010
    Publication date: August 5, 2010
    Applicant: ELI LILLY AND COMPANY
    Inventors: Nuria DIAZ BUEZO, Concepcion PEDREGAL-TERCERO, David Lee MCKINZIE, Charles Howard Mitch
  • Kappa selective opioid receptor antagonist
    Patent number: 7709522
    Abstract: A selective kappa opioid receptor antagonist, (S)-3-Fluoro-4-[4-[2-(3,5-dimethylphenyl)pyrrolidin-1-yl-methyl]phenoxy]benzamide or a pharmaceutically acceptable salt thereof, useful for treating ethanol use disorder withdrawal, and anxiety and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Grant
    Filed: January 13, 2009
    Date of Patent: May 4, 2010
    Assignee: Eli Lilly and Company
    Inventors: Nuria Diaz Buezo, Concepcion Pedregal-Tercero, David Lee McKinzie, Charles Howard Mitch
  • KAPPA SELECTIVE OPIOID RECEPTOR ANTAGONIST
    Publication number: 20090186873
    Abstract: A selective kappa opioid receptor antagonist useful for treating ethanol use disorder withdrawal and anxiety, and/or depression, or schizophrenia as independent comorbid conditions.
    Type: Application
    Filed: January 13, 2009
    Publication date: July 23, 2009
    Inventors: Nuria Diaz Buezo, Concepcion Pedregal-Tercero, David Lee McKinzie, Charles Howard Mitch
  • Diaryl ethers as opioid receptor antagonists
    Patent number: 7560463
    Abstract: Compound 5-(2-Methoxy-4-{[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl}-phenoxy)-pyrazine-2-carboxamide or a pharmaceutically acceptable salt thereof, useful for the treatment of irritable bowel syndrome.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: July 14, 2009
    Assignee: Eli Lilly and Company
    Inventors: Charles Howard Mitch, Michael Angelo Statnick
  • Diaryl ethers as opioid receptor antagonists
    Patent number: 7531557
    Abstract: Compound 6-(2-fluoro-4-[[2-(tetrahydro-pyran-4-yl)-ethylamino]-methyl]-phenoxy)-nicotinamide, or a pharmaceutically acceptable salt thereof, is useful for the treatment of alcoholism.
    Type: Grant
    Filed: March 21, 2008
    Date of Patent: May 12, 2009
    Assignee: Eli Lilly and Company
    Inventor: Charles Howard Mitch
  • DIARYL ETHERS AS OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080269296
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z. A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: March 21, 2008
    Publication date: October 30, 2008
    Inventors: Maria-Jesus Blanco-Pillado, Mark Donald Chappell, Marta Garcia De La Torre, Nuria Diaz Buezo, James Erwin Fritz, William Glen Holloway, James Edward Matt, Charles Howard Mitch, Concepcion Pedregal-Tercero, Steven James Quimby, Miles Goodman Siegel, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi, Elizabeth Marie Thomas, Chad Nolan Wolfe
  • OPIOID RECEPTOR ANTAGONISTS
    Publication number: 20080207701
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Application
    Filed: April 2, 2008
    Publication date: August 28, 2008
    Inventors: Mark Donald Chappell, Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel
  • Opioid receptor antagonists
    Patent number: 7414132
    Abstract: A compound of the formula (I); wherein the variables X1 to X10, R1 to R7 including R3?, E, W, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Grant
    Filed: December 15, 2004
    Date of Patent: August 19, 2008
    Assignee: Eli Lilly and Company
    Inventors: Marta Garcia De La Torre, Nuria Diaz Buezo, Prabhakar Kondaji Jadhav, Charles Howard Mitch, Concepcion Pedregal-Tercero
  • Opioid receptor antagonists
    Patent number: 7396943
    Abstract: A compound of the formula I: (I) wherein the variables are as described herein, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixture thereof, formulations and methods of use thereof are disclosed.
    Type: Grant
    Filed: March 1, 2004
    Date of Patent: July 8, 2008
    Assignee: Eli Lilly and Company
    Inventors: Dana Rae Benesh, Maria Jesus Blanco-Pillado, Charles Howard Mitch, Kumiko Takeuchi
  • Diaryl ethers as opioid receptor antagonist
    Patent number: 7381719
    Abstract: A compound of the formula (I) wherein the variables X1 to X10, R1 to R7 including R3?, E, v, y, z, A and B are as described, or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed
    Type: Grant
    Filed: September 17, 2003
    Date of Patent: June 3, 2008
    Assignee: Eli Lilly and Company
    Inventors: Maria-Jesus Blanco-Pillado, Marta Garcia De La Torre, Nuria Diaz Buezo, William Glen Holloway, James Edward Matt, Charles Howard Mitch, Concepcion Pedregal-Tercero, Dana Rae Smith, Russell Dean Stucky, Kumiko Takeuchi
  • Amino-phenoxymethyl-benzamide opioid receptor antagonists
    Patent number: 7381750
    Abstract: A compound of the formula (I) wherein the variables X1, X2, R1 to R7 including R3?, j, k, p, y, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed.
    Type: Grant
    Filed: March 8, 2005
    Date of Patent: June 3, 2008
    Assignee: Eli Lilly and Company
    Inventors: Marta Garcia De La Torre, Charles Howard Mitch
  • Diphenylether amide derivatives as opioid receptor antagonists
    Patent number: 7378448
    Abstract: A compound of the formula (I) wherein the variables X1, X2, B, D, R1 to R7 including R3?, p, y, q, and z, are as defined or a pharmaceutically acceptable salt, solvate, enantiomer, racemate, diastereomer or mixtures thereof, useful for the treatment, prevention or amelioration of obesity and Related Diseases is disclosed
    Type: Grant
    Filed: March 2, 2005
    Date of Patent: May 27, 2008
    Assignee: Eli Lilly and Company
    Inventors: Charles Howard Mitch, Steven James Quimby, Miles Goodman Siegel